854778-61-3

Basic information

• Product Name: (1-METHYL-1H-INDOL-7-YL)METHANOL
• Synonyms: (1-METHYL-1H-INDOL-7-YL)METHANOL
• CAS NO: 854778-61-3
• Molecular Formula: C₁₀H₁₁NO
• Molecular Weight: 161.2
• Mol File: 854778-61-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1-METHYL-1H-INDOL-7-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (1-METHYL-1H-INDOL-7-YL)METHANOL(854778-61-3)
• EPA Substance Registry System: (1-METHYL-1H-INDOL-7-YL)METHANOL(854778-61-3)

Safety Data

• Hazardous Substances Data: 854778-61-3(Hazardous Substances Data)

Upstream product

• 552-89-6 2-nitro-benzaldehyde 
• 53951-34-1 o-nitrobenzaldehyde dibutyl acetal 
• 69047-36-5 1-methyl-1H-indole-7-carboxaldehyde 
• 1074-88-0 1H-indole-7-carbaldehyde 
• 1074-87-9 indole-7-methanol 
• 74-88-4 methyl iodide 

Downstream Products

• 1215385-16-2 7-formyl-1-methyl-1H-indole-2-carboxylic acid N-methyl-morpholine salt 
• 854772-57-9 3-benzyl-4-{3-[(1-methyl-1H-indol-7-yl)methoxy]phenyl}-8-(trifluoromethyl)quinoline 

Relevant articles and documents

Benzimidazolone as potent chymase inhibitor: Modulation of reactive metabolite formation in the hydrophobic (P1) region

A new class of chymase inhibitor featuring a benzimidazolone core with an acid side chain and a P1 hydrophobic moiety is described. Incubation of the lead compound with GSH resulted in the formation of a GSH conjugate on the benzothiophene P1 moiety. Replacement of the benzothiophene with different heterocyclic systems such as indoles and benzoisothiazole is feasible. Among the P1 replacements, benzoisothiazole prevents the formation of GSH conjugate and an in silico analysis of oxidative potentials agreed with the experimental outcome.

7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases

The present invention provides compounds according to general formula (I) which are proposed for the treatment of respiratory complaints, particularly asthma and COPD.

From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells

Recent studies have demonstrated that glycogen synthase kinase 3β (GSK-3β) is overexpressed in human colon and pancreatic carcinomas, contributing to cancer cell proliferation and survival. Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl) maleimides, potent GSK-3β inhibitors. Some of these compounds show picomolar inhibitory activity toward GSK-3β and an enhanced selectivity against cyclin-dependent kinase 2 (CDK-2). Selected GSK-3β inhibitors were tested in the pancreatic cancer cell lines MiaPaCa-2, BXPC-3, and HupT3. We determined that some of these compounds, namely compounds 5, 6, 11, 20, and 26, demonstrate antiproliferative activity against some or all of the pancreatic cancer cells at low micromolar to nanomolar concentrations. We found that the treatment of pancreatic cancer cells with GSK-3β inhibitors 5 and 26 resulted in suppression of GSK-3β activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis. The present data suggest a possible role for GSK-3β inhibitors in cancer therapy, in addition to their more prominent applications in CNS disorders.